Elixiron Immunotherapeutics (Cayman) Limited Company Description

Elixiron Immunotherapeutics (Cayman) Limited engages in the development of immunotherapies for cancer and immune diseases in the United States.

It develops EI-1071, a small molecule inhibitor of CSF-1R used for the treatment of Alzheimer's disease and amyotrophic lateral sclerosis; EI-001 for the treatment of vitiligo and hemophagocytic lymphohistiocytosis (HLH); and EI-012, a monoclonal antibody and EI-220 mRNA for the treatment of cancer.

It also offers mRNA drug development platform, which focuses on in-vivo expression of biologics, accelerating the process from laboratory to clinical treatment.

Elixiron Immunotherapeutics (Cayman) Limited was incorporated in 2017 and is headquartered in Taipei, Taiwan.

Elixiron Immunotherapeutics (Cayman) Limited

Country	Cayman Islands
Founded	2017
Industry	Biological Products, Except Diagnostic Substances
CEO	Hung-Kai Chen

Contact Details

Address: No. 508, Section 7 Taipei, 115011 Taiwan
Phone	886 2 2782 7700
Website	elixiron.com

Stock Details

Ticker Symbol	7871
Exchange	Taipei Exchange
Fiscal Year	January - December
Reporting Currency	TWD
SIC Code	2836

Key Executives

Name	Position
Hung-Kai Chen	Chief Executive Officer
James Hsu	Chief Financial Officer